Atrial fibrillation (AF) is the most common type of cardiac arrhythmia. An arrhythmia is a problem with the rate or rhythm of the heartbeat. The purpose of the study is to see whether an investigational medical device called the DiamondTemp Ablation Catheter (also called the DiamondTemp Ablation System) can restore the heart to a normal heart rhythm. Every participant will receive the same treatment, radiofrequency (RF) ablation, for atrial fibrillation with the DiamondTemp Ablation System. The results of this study may be used to help the Food and Drug Administration (FDA) determine if the device should be approved in the USA.
The purpose of this clinical study is to see whether a medical device called the Paradise Renal Denervation System (also called The Paradise System) can lower high blood pressure in participants who are known to have hypertension. The device and the treatment delivered by the device, which is known as renal denervation, are investigational in the United States because they haven't been approved by the FDA. Renal denervation is a procedure where a catheter is placed inside these blood vessels (renal arteries). The ultrasound energy is created when the catheter is connected to a power source known as a generator. The ultrasound energy will heat up a small area of tissue around the blood vessel to disable nerves that are surrounding the blood vessels.
Participants will stop taking hypertensive medication before the procedure and up to two months after the procedure. Participants will be randomized to the procedure or control and will be followed for 36 months. At the six month follow-up appointment, participants will learn whether they had the procedure or not. Those who did not receive the procedure can opt in to have the procedure in the future.
The purpose of this study is to evaluate causes and risk factors for liver disease in those whom have 1) undergone the Fontan procedure or 2) whom have dilated cardiomyopathy.
Participants in this study will have a blood sample collected, undergo cardiac magnetic resonance imaging (CMR), a liver magnetic resonance imaging (MRI), shear wave ultrasound elastography (SWE), echocardiography, liver Doppler ultrasound, and an exercise stress test. Participants medical records will be reviewed to collect information on previous medical procedures. Participation is complete once all imaging studies and blood sample have been collected.
This is not a treatment study; if one chooses not to participate, s/he will continue to undergo regularly scheduled clinical procedures.
The purpose of the study is to generate a bio bank of specimens for research. We will tissue that would otherwise be discarded from clinical or surgical procedure and information from medical records. We will also collect discarded blood, urines and sputum. Collecting samples will help to better understanding the mechanisms of cardiovascular diseases, identify biomarkers for early diagnosis and to predict safety and efficacy of new therapies.
The purpose of this trial is to test if a marketed drug for advanced prostate cancer (FIRMAGON) can reduce the risk of cardiovascular complications as compared to another marketed drug for advanced prostate cancer (LUPRON DEPOT) in patients with prostate cancer and cardiovascular disease.
The purpose of this research is to test a new experimental drug called "AG10" made by Eidos Therapeutics, to find out if this new drug is safe and if it works to help patients with Amyloidosis Cardiomyopathy. This is a follow up of the AG10-201 study in which participants were randomized to either study drug or placebo. It is only open to participants who completed the AG10-201 study. It will consist of 4 clinic visits and take less than three months for the participants to complete.
The purpose of the study is to show that the FlexAbility™ SE Ablation Catheter is safe and effective in reducing the number of Ventricular Tachycardia (VT) episodes in patients who continue to experience VT despite taking antiarrhythmic medications (medicines to prevent abnormal heart rhythms), or who are unable to take antiarrhythmic medications. Subject should be at least 18 years old. The entire duration of the study will be one year from the ablation procedure and consists of four follow up visits after the ablation procedure.
Heart failure affects over one million Americans and thousands of new cases are diagnosed each year. This syndrome tends to be progressive and is associated with an increased risk for hospitalizations and possbile death. The CardioMEMS™ HF System is an FDA approved device for individuals with class III heart failure. The system is placed in your heart during a short procedure. Following placement, your doctor is able to monitor the pressures in your heart from the comfort of your own home.The GUIDE-HF study will investigate to determine if the device is effective in individuals with class II, III, or IV heart failure with elevated labs and/or those who have had prior heart failure hospitalizations. During the study, patients will be seen 6 times in our research clinic. During these visits the study staff will ask you to fill out questionnaires, measure your vital signs (blood pressure, heart rate, weight), perform a 6 minute hall walk, draw blood to look at your heart function, and review medications. The device is permanent after implant.
Roughly 8-10 million patients complaining of chest pain come to an Emergency Department (ED) annually in the United States. Quickly determining if you are having a heart attack is critical for improving your chances of survival. Cardiac troponin is a protein that is used as a biomarker (biological marker) to indicate damage to the heart muscle. Cardiac troponin lab tests that are currently used in the United States do not have the ability to detect low levels of troponin. There are more sensitive troponin tests that are primarily used outside the US, that are able to detect lower levels of cardiac troponin within 90-180 minutes instead of 5 or 6 hours. This allows for the early identification of individuals at a higher risk for heart damage and these patients benefit from early diagnosis and treatment. Delaying the treatment of a heart attack increases the chance of dying or being permanently disabled. This study will collect blood samples from people coming to the Emergency Department complaining of chest pain in order to measure this troponin lab test's ability to accurately detect troponin levels.
Cardiac implantable electronic devices (Implantable Cardioverter Defibrillators (ICD),cardiac resynchronization therapy (CRT)) with sensors have been used to develop Heart Failure diagnostics which indicate early changes leading up to hospitalizations. The study is testing a feature that can help predict when your heart failure is getting worse. The feature is called HeartLogic™ Heart Failure Diagnostic Service, or simply HeartLogic.